Description of Research Expertise:
The Vonderheide laboratory combines efforts in both basic research and clinical investigation to advance the understanding of tumor immunology and to develop novel immunotherapies for cancer. The chief hypothesis is that successful approaches in tumor immunotherapy will need to (a) optimize target antigens with regard to clinical applicability and risk of antigen loss, (b) repair host immuno-incompetence in antigen presentation and T cell function, and (c) circumvent immuno-suppressive factors of the tumor and tumor microenvironment.
Dr. Vonderheide’s basic research includes deciphering the immunobiology of novel genetically engineered mouse models of cancer, including the regulation of immune surveillance and the tumor microenvironment by CD40 and other pathways, and with a focus on pancreatic cancer, breast cancer, and melanoma. His translational work tests novel approaches such as vaccines, antibodies, and adoptive T cells for the treatment of patients with melanoma, pancreatic cancer and other cancers. He has studied ‘universal’ tumor antigens, immune effects of radiation, and immune modulatory pathways involving CD40, GM-CSF, PD-1, CTLA-4, and CD25. Publications include those in high-impact journals such as Nature, Science, Cell, and the New England Journal of Medicine.
Robert Vonderheide, MD, DPhil
Director, Abramson Cancer Center; John H. Glick MD Abramson Cancer Center's Professor
Nune Markosyan, MD, PhD, Laboratory Director
Katelyn Byrne, PhD, Instructor in Medicine
Mark Diamond, MD, PhD, Instructor in Medicine
Adham Bear, MD, PhD, Clinical Fellow
Alex Morrison, MD, TRM Student
Bereket Gebregziabher, undergraduate student
Ceire Hay, research specialist
Austin Huffman, Graduate Student (PhD, Immunology)
Jeffrey Lin, Graduate Student (MD/PhD)
Liz Quinones, research specialist
Andrew Rech, Post-doctoral Scholar (MD/PhD)
Lee Richman, Graduate Student (MD/PhD)
Mark Sudell, Administrator, 215-746-8901; firstname.lastname@example.org
Bajor David L, Xu Xiaowei, Torigian Drew A, Mick Rosemarie, Garcia Laura R, Richman Lee P, Desmarais Cindy, Nathanson Katherine L, Schuchter Lynn M, Kalos Michael, Vonderheide Robert H: Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma. Cancer immunology research 2 (11): 1051-8,2014.
Condamine Thomas, Kumar Vinit, Ramachandran Indu R, Youn Je-In, Celis Esteban, Finnberg Niklas, El-Deiry Wafik S, Winograd Rafael, Vonderheide Robert H, English Nickolas R, Knight Stella C, Yagita Hideo, McCaffrey Judith C, Antonia Scott, Hockstein Neil, Witt Robert, Masters Gregory, Bauer Thomas, Gabrilovich Dmitry I: ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. The Journal of clinical investigation 124 (6): 2626-39,2014.
Zhang Yaqing, Yan Wei, Mathew Esha, Bednar Filip, Wan Shanshan, Collins Meredith A, Evans Rebecca A, Welling Theodore H, Vonderheide Robert H, di Magliano Marina Pasca: CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice. Cancer immunology research 2 (5): 423-35,2014.
Richman Lee P, Vonderheide Robert H: Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer. Cancer immunology research 2 (1): 19-26,2014.
Mueller Christian, Chulay Jeffrey D, Trapnell Bruce C, Humphries Margaret, Carey Brenna, Sandhaus Robert A, McElvaney Noel G, Messina Louis, Tang Qiushi, Rouhani Farshid N, Campbell-Thompson Martha, Fu Ann Dongtao, Yachnis Anthony, Knop David R, Ye Guo-Jie, Brantly Mark, Calcedo Roberto, Somanathan Suryanarayan, Richman Lee P, Vonderheide Robert H, Hulme Maigan A, Brusko Todd M, Wilson James M, Flotte Terence R: Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. The Journal of clinical investigation 123 (12): 5310-8,2013.
Markosyan N, Chen EP, Evans RA, Ndong V, Vonderheide RH, Smyth EM: Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity. Breast Cancer Research 15 (5): R75 [Epub ahead of print],2013.
Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, O'Dwyer P: A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clinical Cancer Research : [Epub ahead of print],2013.
Bayne LJ, Vonderheide RH: A myeloid-derived suppressor cell-mediated T-cell suppression assay for functional evaluation of immune cells in tumor-bearing mice.
Cold Spring Harb Protoc. 2013 (9): 2013.
Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW, Hamid O: Phase I study of CD40 antibody CP-870,893 in combination
with carboplatin and paclitaxel in patients with advanced solid tumors
OncoImmunology 2 : e23033,2013.
Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, Kalos M, Vonderheide RH, Albelda SM, June CH, Zhang PJ.: Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Can Res Treat 133 : 799-804,2012.
View all publications